aTyr Pharma ATYR Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about aTyr Pharma's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is aTyr Pharma's operating lease right-of-use asset amortization?
- aTyr Pharma (ATYR) reported operating lease right-of-use asset amortization of $232K in Q1 2026.
- How has aTyr Pharma's operating lease right-of-use asset amortization changed year-over-year?
- aTyr Pharma's operating lease right-of-use asset amortization increased by 7.4% year-over-year, from $216K to $232K.
- What is the long-term trend for aTyr Pharma's operating lease right-of-use asset amortization?
- Over 3 years (2021 to 2025), aTyr Pharma's operating lease right-of-use asset amortization has grown at a 2.4% compound annual growth rate (CAGR), from $829K to $889K.